Institutional Repository in Medical Sciences
(IRMS – Nicolae Testemițanu SUMPh)

Malignant neuroleptic syndrome in the use of atypical neuroleptics in the treatment of schizophrenia

Show simple item record

dc.contributor.author Chilari, Mihaela
dc.contributor.author Chianu, Marin
dc.date.accessioned 2020-11-22T15:21:13Z
dc.date.available 2020-11-22T15:21:13Z
dc.date.issued 2020-10
dc.identifier.uri https://stiinta.usmf.md/ro/manifestari-stiintifice/zilele-universitatii
dc.identifier.uri http://repository.usmf.md/handle/20.500.12710/13145
dc.description Chair Psychiatry narcology and medical psychology, SMUPh ”Nicolae Testemitanu”, Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină și Farmacie „Nicolae Testemițanu” din Republica Moldova, Ziua internațională a științei pentru pace și dezvoltare en_US
dc.description.abstract Introduction Neuroleptic malignant syndrome (NMS) as an adverse reaction to the use of atypical neuroleptics (AN) is present in 0.02 - 3 % of patients, being determined by age, sex, diagnosis and the group of atypical neuroleptics that were administered. Purpose Analysis and systematization of the adverse reactions (neuroleptic malignant syndrome) produced by atypical neuroleptics. Material and methods The articles from the PubMed and MEDLINE database were selected and analyzed according to the keywords “neuroleptic malignant syndrome”, “atypical antipsychotic drugs”, “treatment of schizophrenia”. Results The pathophysiology of this adverse reaction is not fully elucidated, a hypothesis is the rapid blockade of D2 receptors in the CNS. NMS includes such symptoms as: instability, extrapyramidal disorders, hyperpyrexia, and altered mental state. When using AN as clozapine, risperidone, olanzapine and quentiapine SNM occurred on average on the 14th day. Thus, on the background of the treatment with clozapine SNM was manifested in 30%, in the administration of risperidone in 38%, in the administration of olanzapine in 27%, and quentiapine in 5% of cases. Conclusions Thus, we can say that in terms of treatment with AN, the SNM rate is lower than with the use of typical neuroleptics or it may simply be a reflection of doctors' awareness and the follow-up of early treatment with more harmless and contemporary drugs. en_US
dc.language.iso en en_US
dc.publisher Universitatea de Stat de Medicină şi Farmacie "Nicolae Testemiţanu" din Republica Moldova en_US
dc.subject neuroleptic malignant syndrome en_US
dc.subject atypical neuroleptics en_US
dc.title Malignant neuroleptic syndrome in the use of atypical neuroleptics in the treatment of schizophrenia en_US
dc.type Other en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics